New drug tested for Hard-to-Treat bowel disease
NCT ID NCT05377580
Summary
This study tested an investigational drug called IBI112 for people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 150 participants received either the drug or a placebo to see if it could help achieve and maintain clinical remission over a year. The main goal was to see if the drug was effective at reducing disease activity and improving symptoms like rectal bleeding and stool frequency.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.